The Valley Desk

ArticleLeukemiaPublished

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Leukemia
Published
PubMed ID
42839070
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal